Please assess the completion status of the following clinical trial:

Trial Title: Study of Picibanil (OK432) Sclerotherapy in Children With Macrocystic Lymphatic Malformations

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
PROTOCOL ENTRY CRITERIA:~--Disease Characteristics--~* Diagnosis of macrocystic lymphangioma of the head and/or neck Cystic spaces at least 2.0 mL confirmed by radiographic imaging (MRI or CT) Mixed lymphangiomas (macrocystic and microcystic disease) allowed if macrocystic component comprises at least 50% of the total disease burden~* No mixed hemangioma-lymphangioma lesions~* At least 6 months since prior surgery for lymphangioma~--Patient Characteristics--~* Hematopoietic: No clinically significant hematologic disease No hemodynamic instability~* Hepatic: No clinically significant hepatic disorder~* Renal: No clinically significant renal disease No personal or family history of post-streptococcal glomerulonephritis~* Cardiovascular: No personal or family history of rheumatic heart disease~* Pulmonary: No respiratory failure~Other:~* Not pregnant or nursing~* Negative pregnancy test~* No history of allergy to penicillin~* No concurrent temperature of 100.5 degrees or greater~* No active upper respiratory infection~* No personal or family history of obsessive-compulsive or tic disorders~* No personal or family history of PANDA (pediatric autoimmune neuro- psychiatric disorder associated with streptococcal infections)~* No history of hypersensitivity to iodine, Omnipaque, or gadolinium (if fluoroscopy is considered necessary)~* No history of poor health (including congenital disorders, chronic diseases, or immunologic dysfunction)

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).